Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China flag China · Delayed Price · Currency is CNY
5.03
-0.11 (-2.14%)
Nov 13, 2026, 3:04 PM CST

Beijing SL Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-838.43-347.2-74.07416.69234.4425.94
Depreciation & Amortization
166.76166.77152.96145.4113.8899.8
Other Amortization
0.30.290.280.280.170.17
Loss (Gain) From Sale of Assets
0.050.05---0.21-3.22
Asset Writedown & Restructuring Costs
-338.17-338.17172.29-0.0100.02
Loss (Gain) From Sale of Investments
-2.34-2.34-13.13-239.47-98.13-209.01
Provision & Write-off of Bad Debts
---23.8131.9426.25
Other Operating Activities
788.06-0.23-0.661.05-5.99-4.38
Change in Accounts Receivable
-14.76-14.7662.4519.6682.88108.64
Change in Inventory
-436.26-436.26-102.33-4.250.58-11.5
Change in Accounts Payable
544.68544.6868.5166.5836.5617.54
Change in Other Net Operating Assets
621.15621.1511.09---
Operating Cash Flow
554.72257.66225.49460.2389.82464.63
Operating Cash Flow Growth
504.11%14.27%-51.00%18.05%-16.10%11.73%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-56.93-192.97-347.38-218.36-163.49-236.91
Sale of Property, Plant & Equipment
0000.011.477.49
Divestitures
-----4.88-
Investment in Securities
-422.8726.4-33.46-86.95-384.76-0.96
Other Investing Activities
34.0127.29169.29-39.3511.2532.55
Investing Cash Flow
-445.79-139.28-211.55-344.65-540.4-197.82

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-----5.5
Total Debt Issued
-----5.5
Short-Term Debt Repaid
------14.5
Long-Term Debt Repaid
------0.4
Lease Payments
------0.4
Total Debt Repaid
------14.9
Net Debt Issued (Repaid)
------9.4
Common Dividends Paid
-7.59-17.9-154.1-102.74-102.74-102.93
Other Financing Activities
-----9
Financing Cash Flow
-7.59-17.9-154.1-102.74-102.74-103.33

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-00-00.030.1-0.02
Net Cash Flow
101.33100.49-140.1712.84-253.21163.45

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
497.7964.69-121.89241.84226.33227.72
Free Cash Flow Growth
---6.85%-0.61%42.42%
Free Cash Flow Margin
89.59%10.37%-18.46%23.75%21.55%18.75%
Free Cash Flow Per Share
0.490.06-0.120.240.220.22
Levered Free Cash Flow
1,415-36.59-260.4186.77121.34113.97
Unlevered Free Cash Flow
1,415-36.59-260.4186.77121.4114.11
Free Cash Flow After Leases
497.7964.69-121.89241.84226.33227.32

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
48.3726.639.1488.1691.5585.63
Change in Working Capital
778.49778.49-12.18112.45113.75129.06